The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001027303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
17/07/2026
Date registered
Help: Date registered
20/08/2026
Date last updated
Help: Date last updated
20/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility, usability, acceptability and efficacy of virtual reality rehabilitation for Complex Regional Pain Syndrome (CRPS)
Scientific title
The feasibility, usability, acceptability and efficacy of a novel virtual reality rehabilitation programme for Complex Regional Pain Syndrome (CRPS): A single case experimental design multiple baseline study
Additional trial identifiers [1] 317944 0
Nil
Universal Trial Number (UTN)
U1111-1344-1418
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Complex Regional Pain Syndrome (CRPS) 342898 0
Condition category
Condition code
Anaesthesiology 339019 339019 0 0
Pain management
Physical Medicine / Rehabilitation 339299 339299 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The Intervention
The intervention is a 6-week Virtual Reality rehabilitation programme.
VR Intervention Procedure:
Participants will use a Meta Quest 3 virtual reality headset to engage with a custom-designed software application (“Happihands”) that presents a 3D model of their hands within an immersive virtual environment. The intervention is designed to support upper limb rehabilitation for individuals with CRPS.
Each session will follow a structured format:
1. Hand Visual Manipulation (3–5 minutes)
At the beginning of each session, participants will be prompted to modify the visual appearance of their affected (virtual) hand and individual fingers. Available adjustments include:
a. Size
b. Shape
c. Transparency
d. Colour/skin tone
These modifications are intended to reflect individual preferences and promote a sense of ownership and connection with the affected limb.
2. Rehabilitation Task (15–20 minutes)
Following the visual manipulation phase, participants will engage in a rehabilitation game involving timed block building. The game includes five levels of complexity (each involving more blocks and more complex designs) and is designed to provide:
a. Visually stimulating and engaging hand movements
b. Progressive motor challenges
c. Repetitive, goal-directed activity known to support neuroplasticity and functional recovery in CRPS

The intervention is delivered remotely to individuals at home with VR headsets delivered to participants by courier. Participants are provided with a custom-developed training booklet, custom-developed instructional video, and a 30-60 minute therapist-led video conference for training, as to the first scheduled VR session. Participants will have the opportunity to contact the therapist throughout the trial. The therapist is a pain specialist physiotherapist with 20 years clinical experience.

Participants are asked to complete 5 sessions/week for 6 weeks.

Usage data is collected within the software, with adherence data downloaded once VR headsets are returned to the research team.


Intervention code [1] 334809 0
Rehabilitation
Description of the comparator or control
The study utilises a single case experimental design so each participant acts as their own control.
Participants will be randomised to complete a 3, 4, 5, or 6 week baseline period of usual care prior to the VR intervention. Usual care may include regular physical therapies, psychological interventions and analgesic medications but participants will be required to have stable treatment for 4 weeks prior to the start of the trial and not start any new treatment during the study period.
Control group
Active

Outcomes
Primary outcome [1] 346259 0
Pain Intensity
Timepoint [1] 346259 0
Twice weekly during the baseline period (3, 4 ,5 or 6 weeks), twice weekly during the intervention period (6 weeks), twice weekly during the first 4 weeks of follow-up. Then measured once only at 12 week follow-up.
Primary outcome [2] 346260 0
Pain Interference
Timepoint [2] 346260 0
Twice weekly during the baseline period (3, 4 ,5 or 6 weeks), twice weekly during the intervention period (6 weeks), twice weekly during the first 4 weeks of follow-up. Then measured once only at 12 week follow-up.
Primary outcome [3] 346261 0
Limb Ownership
Timepoint [3] 346261 0
Twice weekly during the baseline period (3, 4 ,5 or 6 weeks), twice weekly during the intervention period (6 weeks), twice weekly during the first 4 weeks of follow-up. Then measured once only at 12 week follow-up.
Secondary outcome [1] 465244 0
Pain Intensity
Timepoint [1] 465244 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [2] 465245 0
Pain Interference
Timepoint [2] 465245 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [3] 465246 0
Function
Timepoint [3] 465246 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [4] 465247 0
Depression
Timepoint [4] 465247 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [5] 465248 0
Anxiety
Timepoint [5] 465248 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [6] 465249 0
Stress
Timepoint [6] 465249 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [7] 465250 0
Body Perception Disturbance
Timepoint [7] 465250 0
Pre-baseline (week 0), End of baseline/start of intervention (between 3-6 weeks post-baseline), End of 6-week intervention, 4-week post-intervention completion follow-up, 12-week post-intervention completion follow-up.
Secondary outcome [8] 465251 0
Feasibility: Recruitment Rates
Timepoint [8] 465251 0
At the end of recruitment once final participant has been enrolled into the study.
Secondary outcome [9] 465252 0
Usability: Independence of Use
Timepoint [9] 465252 0
At the completion of the 6-week intervention phase.
Secondary outcome [10] 465253 0
Acceptability: Safety and tolerability
Timepoint [10] 465253 0
Weekly monitoring throughout the 21-24week study period
Secondary outcome [11] 466223 0
Feasibility: Loss to Follow-Up
Timepoint [11] 466223 0
Completion of trial (i.e. following final participant's 12-week follow-up)
Secondary outcome [12] 466224 0
Feasibility: Adherence to sessions
Timepoint [12] 466224 0
At the completion of 6-week intervention phase
Secondary outcome [13] 466225 0
Usability & Acceptability: Semi-structured Interviews
Timepoint [13] 466225 0
At the completion of the 6-week intervention phase.

Eligibility
Key inclusion criteria
To be eligible for the study, participants will satisfy the following criteria:
• Aged 18 or over
• Pain intensity of greater than or equal to 4/10 on average in the last week at the time of screening
• Formal diagnosis of CRPS in one upper limb only as per Budapest clinical criteria
• Stable CRPS treatment for at least 4 weeks prior to baseline measurement

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded from the study if they have:
a. Current health condition that is likely to prevent engagement with the intervention (e.g. cognitive impairment, recent stroke)
b. Inability to communicate in English
c. A history of severe motion sickness, epilepsy or (uncorrected) visual impairment that would prevent VR use
d. Plan to begin any new CRPS treatments during the 24-week study period
e. Amputation of one or more digits (due to hardware constraints that limit hand tracking technology for this group).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Single case experimental design with randomly allocated baseline periods of 3, 4, 5, or 6 weeks, then all participants complete the intervention period and follow-up.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
CRPS is a rare condition, making recruitment challenging. A sample size of 12 balances methodological rigour with feasibility within the 18-month study timeline and available resources, while providing sufficient data to address both primary and secondary objectives. With respect to the primary objectives, n=12 provides adequate information to assess key feasibility parameters, as well as usability and acceptability of the VR intervention. For demonstration of preliminary efficacy, the sample provides 12 potential demonstrations of treatment effects (3 independent cohorts of 4 participants will be recruited, where each participant in a cohort has a varying baseline duration), substantially exceeding the WWC Version 5.0 minimum requirement of three demonstrations for establishing causal inference in MBAP designs. Three independent cohorts of participants also provide systematic replication, enhancing external validity and protecting against cohort-specific confounds. This replication structure is consistent with recommendations for high-quality single-case experimental design research. NB. The term 'cohort' in this context refers to a group of 4 participants who will be recruited to start the study simultaneously if feasible.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Recruitment outside Australia
Country [1] 28349 0
New Zealand
State/province [1] 28349 0

Funding & Sponsors
Funding source category [1] 322491 0
Other Collaborative groups
Name [1] 322491 0
Te Titoki Mataora Research Accelerator Programme
Country [1] 322491 0
New Zealand
Funding source category [2] 322493 0
Other Collaborative groups
Name [2] 322493 0
Kiwinet Innovation Network PreSeed Funding
Country [2] 322493 0
New Zealand
Primary sponsor type
University
Name
Auckland University of Technology
Address
Country
New Zealand
Secondary sponsor category [1] 325409 0
None
Name [1] 325409 0
Address [1] 325409 0
Country [1] 325409 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320971 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 320971 0
Ethics committee country [1] 320971 0
New Zealand
Date submitted for ethics approval [1] 320971 0
01/04/2026
Approval date [1] 320971 0
05/06/2026
Ethics approval number [1] 320971 0
2026 EXP 23866

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152242 0
A/Prof Debbie Bean
Address 152242 0
Auckland University of Technology, 90 Akoranga Drive, 0627, Northcote, Auckland
Country 152242 0
New Zealand
Phone 152242 0
+64 9 921 9999 7157
Fax 152242 0
Email 152242 0
Contact person for public queries
Name 152243 0
Debbie Bean
Address 152243 0
Auckland University of Technology, 90 Akoranga Drive, 0627, Northcote, Auckland
Country 152243 0
New Zealand
Phone 152243 0
+64 9 921 9999 7157
Fax 152243 0
Email 152243 0
Contact person for scientific queries
Name 152244 0
Debbie Bean
Address 152244 0
Auckland University of Technology, 90 Akoranga Drive, 0627, Northcote, Auckland
Country 152244 0
New Zealand
Phone 152244 0
+64 9 921 9999 7157
Fax 152244 0
Email 152244 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: Maori data sovereignty needs to be considered. Maori data would only be shared with the agreement of Maori cultural advisors in the research team.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.